Verve Therapeutics’ CEO Sekar Kathiresan to Speak at Wall Street Journal Health Forum
CAMBRIDGE, Mass. — March 23, 2020 — Verve Therapeutics, a next-generation cardiovascular company developing therapies that safely edit the adult human genome to permanently reduce a person’s risk of coronary artery disease, today announced that Sekar Kathiresan, M.D., co-founder and chief executive officer, will be a featured speaker at the Wall Street Journal Health Forum on Tuesday, March 24, 2020. Dr. Kathiresan will join a panel discussion on the rising prevalence of heart disease and how we can intervene to tackle this problem. The panel, titled “Case Study: Heart Disease,” will take place at 9:40 a.m. ET.
“Heart disease continues to be the leading cause of death worldwide, with mortality rates among adults ages 45-64 on the rise across the U.S.,” said Dr. Kathiresan. “Existing treatments, including cholesterol-lowering statins and other therapies, have played an important role in treating heart disease, but they are not enough. Our increased understanding of genetics and heart disease has paved the way for the development of gene editing therapies to safely lower LDL cholesterol levels and permanently reduce the risk of heart disease and heart attack. I am honored to participate in this important discussion, and look forward to sharing Verve’s vision to develop a one-time gene editing treatment for adults with or at risk for the disease.”
About Verve Therapeutics
Verve Therapeutics is a biotechnology company created with a singular focus: to protect the world from heart disease. The company brings together human genetics analysis and gene editing — two of the biggest breakthroughs in 21st century biomedicine — to develop transformative therapies for coronary artery disease. Verve is developing gene editing therapies, administered once in life, that safely edit the genome of adults to lower high cholesterol levels and permanently reduce the risk of coronary artery disease and heart attack. Founded by world-leading experts in cardiovascular medicine, human genetics and gene editing, Verve is backed by a top-tier syndicate of investors, including GV (formerly Google Ventures), ARCH Venture Partners, F-Prime Capital, and Biomatics Capital. Verve is headquartered in Cambridge, Massachusetts. For more information, visit www.VerveTx.com.
Media Contact
Lisa Raffensperger, (617) 903-8783
Ten Bridge Communications
lisa@tenbridgecommunications.com
